| Old Articles: <Older 7431-7440 Newer> |
|---|
 |
Pharmaceutical Executive
May 1, 2011
Robert Neumann |
iDeal Tool of Sales Trade The sleek, portable iPad, coupled with customized apps, gives sales reps a leg up.   |
Pharmaceutical Executive
May 1, 2011
Al Topin |
Blame the Driver, Not the Car Why is building a successful pharma marketing program so difficult? It should be simple, if your product is worth marketing. |
Pharmaceutical Executive
May 1, 2011 |
Seeing Through the Transparency Directive The EU is largely powerless when it comes to policies over pharma pricing and reimbursement. |
Pharmaceutical Executive
May 1, 2011
William Looney |
Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. |
Pharmaceutical Executive
May 1, 2011
Cheah Chor Eng |
The Elusive Single-Point-of-Entry Considering Big Pharma's trade objectives, the success of regional regulatory harmonization is not insignificant. |
Pharmaceutical Executive
May 1, 2001 |
On Tour with Merck's Robots Merck's HTS robots move assay plates through the screening process. |
The Motley Fool
May 11, 2011
Brian Orelli |
Boston Scientific Investors' Parting Gift Less than two years in, Elliot is out. |
The Motley Fool
May 11, 2011
Brian Orelli |
Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good. |
The Motley Fool
May 11, 2011 |
One Stem Cell Stock to Avoid Our investing community's latest short pick -- Pluristem Therapeutics. |
The Motley Fool
May 11, 2011
Jared Cummans |
Wednesday's ETF to Watch: iShares MSCI Israel Fund Teva Pharmaceuticals releases earnings today. |
| <Older 7431-7440 Newer> Return to current articles. |
